Insight Molecular Diagnostics Inc. (IMDX) vs Lucid Diagnostics Inc. (LUCD)

A side-by-side comparison of Insight Molecular Diagnostics Inc. and Lucid Diagnostics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — IMDX vs LUCD

growth of $100 · dividends reinvested · last 5y
IMDX -94.7% (-44.3%/yr)LUCD -95.0% (-45.0%/yr)IMDX compounded faster over this window
020406080100Start $10020222023202420252026$5$5
IMDX LUCD

IMDX vs LUCD: by the numbers

  • •IMDX is the larger company ($117M vs $115M market cap).
  • •Both run net losses; LUCD's is the smaller (-959.76% vs -2955.63% net margin).

Metrics side by side

Valuation

MetricIMDXLUCD
P/S ratio70.2821.14
P/B ratioN/A10.53

Profitability

MetricIMDXLUCD
Gross margin11.17%-60.26%
Operating margin-754.08%-1054.82%
Net margin-2955.63%-959.76%
ROEN/A-478.26%
ROIC-223.06%-145.10%

Growth (annualized)

MetricIMDXLUCD
Revenue CAGR (5Y)27.24%N/A
Total return CAGR (5Y)-44.39%N/A

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.